
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is positioned for long-term success due to its innovative and differentiated technology, including the collaboration with ALC that could potentially generate significant milestone payments and royalty payments. Risks to consider include limited adoption due to the need for additional capital equipment, competition, and a potential for dilutive financing. The company has a strong growth potential with its 12-month price target of $11, which is backed by an EV/sales multiple of 1.5x our 2027 sales estimate.
Bears say
RxSight is experiencing underlying weakness in their 2nd quarter results and a decline in sales of their Light Adjustable Lenses (LAL) due to competitive trialing, likely from JNJ's PureSee product. This led to a revenue miss and a downward revision of 2026 revenue guidance to $140-160M. Additionally, the company's high cash burn remains a concern as they continue to invest in developing new LAL products.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares